Citations

Clear

1315 citation(s) found for "Kyle, RA".

Effect of eliminating pre‐discharge transthoracic echocardiogram on outcomes after TAVR
Welle, Garrett A. , El‐Sabawi, Bassim , Thaden, Jeremy J. , Greason, Kevin L. , Klarich, Kyle W. , Gulati, Rajiv , Rihal, Charanjit S. , Eleid, Mackram F. , Alkhouli, Mohamad A, Eleid, Mackram F , Welle, Garrett A , Nkomo, Vuyisile T. , Alkhouli, Mohamad , Guerrero, Mayra , Crestanello, Juan A. , Rihal, Charanjit S.

Mayo Clinic

Catheterization and Cardiovascular Interventions | August 13, 2021 | Volume: 99 | Issue: 3 | Pages: 861-866

10.1002/ccd.29929 | PMID 34388299 Get It

AbstractObjectivesThe aim of this study was to determine the safety of eliminating the pre‐discharge transthoracic echocardiogram (TTE) on 30‐day outcomes in patients undergoing transcatheter aortic valve replacement (TAVR).BackgroundTTE is utilized before, during, and after TAVR. Post‐procedural, pre‐discharge TTE assists in assessment of prosthesis function and detection of clinically significant paravalvular leak (PVL) after TAVR.MethodsPatients who underwent TAVR at Mayo Clinic from July 2018 to July 2019 were included in a prospective institutional registry. Patients undergoing TAVR prior to February 2019 received a pre‐discharge TTE, while those undergoing TAVR after February 2019 did not. Both cohorts were evaluated with TTE at 30 days post‐TAVR.ResultsA total of 330 consecutive patients were included. Of these, 160 patients (age 81.1 ± 7.6) had routine pre‐discharge TTE, while 170 patients (age 78.9 ± 7.5) were dismissed without routine pre‐discharge TTE. Mortality at 30 days was similar between the two groups (0% and 1.2%, respectively). One episode of PVL requiring intervention (0.6%) occurred in the pre‐discharge TTE group and none in the group without pre‐discharge TTE at 30‐day follow‐up. There was a similar incidence of total composite primary and secondary adverse events between the cohort receiving a pre‐discharge TTE and those without (28.1% vs. 25.3%, P = 0.56) at 30 days. The most common event was need for permanent pacemaker or ICD implantation in both groups (13.1% vs. 11.8%, P = 0.71).ConclusionsElimination of the pre‐discharge TTE is safe and associated with comparable 30‐day outcomes to routine pre‐discharge TTE. These findings have implication for TAVR practice cost‐efficiency and health care utilization.
Dramatic Presentation of Cardiac Pleomorphic Liposarcoma
Tan, Nicholas Y. , Najam, Maria , Lyle, Melissa , Maleszewski, Joseph J. , Collins, Jeremy D. , Klarich, Kyle W. , Lyle, Melissa A. , Collins, Jeremy

Mayo Clinic

Circulation: Cardiovascular Imaging | August 13, 2021 | Volume: 14 | Issue: 8 | Pages: No page available

10.1161/circimaging.121.012620 | PMID 34387092 Get It

Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia
Zanwar, Saurabh , Abeykoon, Jithma P. , Ansell, Stephen M. , Colby, Colin , He, Rong , Warsame, Rahma , Greipp, Patricia T. , King, Rebecca L. , Thompson, Carrie A. , Lacy, Martha Q. , Nowakowski, Grzegorz S. , Dingli, David , Kyle, Robert A. , Kumar, Shaji , Kapoor, Prashant , Larson, Dirk, Paludo, Jonas , He, Rong , Gonsalves, Wilson , Kumar, Shaji K , Kapoor, Prashant , Dingli, David , Greipp, Patricia T , Gertz, Morie A. , Larson, Dirk R. , Paludo, Jonas , Witzig, Thomas E. , Gonsalves, Wilson I. , Go, Ronald S. , Habermann, Thomas M. , Rajkumar, S. Vincent

Mayo Clinic

British Journal of Haematology | August 2, 2021 | Volume: 195 | Issue: 2 | Pages: 210-216

10.1111/bjh.17691 | PMID 34340248 Get It

SummaryPatients with asymptomatic/smouldering Waldenström macroglobulinaemia (SWM) have a variable risk of progression to active WM. Our study evaluated 143 patients with SWM consecutively seen between January 1996 and December 2013. With a median [95% confidence interval (CI)] follow‐up of 9·5 [8·1–11·5] years, the cumulative rate of progression was 11% at 1 year, 38% at 3 years and 55% at 5 years. On multivariate analysis, haemoglobin (Hb) ≤123 g/l [risk ratio (RR) 2·08; P = 0·009] and β2‐microglobulin (β2M) ≥2·7 µg/ml (RR 2·0; P = 0·01) were independent predictors of a shorter time‐to‐progression (TTP) to active WM. Patients with myeloid differentiation factor 88 wild type (MYD88WT) genotype (n = 11) demonstrated a trend toward shorter TTP [median (95% CI) 1·7 (0·7–8·7) vs. 4·7 (2·4–7·7) years for the MYD88L265P cohort, n = 42; P = 0·11]. The presence of C‐X‐C chemokine receptor type 4 (CXCR4) mutation (n = 29) did not impact the TTP (median: 3 years for CXCR4WT vs. 5·6 years for CXCR4MUT, P = 0·34). The overall survival (OS) for patients with SWM (median: 18·1 years) was comparable to an age‐, sex‐ and calendar year‐matched USA population (median: 20·3 years, P = 0·502). In conclusion, Hb and β2M at diagnosis represent independent predictors of progression to active WM. Comparable survival of SWM and a matched USA population argues against pre‐emptive intervention in this patient population.
EphA2 Is a Lung Epithelial Cell Receptor for Pneumocystis β-Glucans
Kottom, Theodore J. , Schaefbauer, Kyle, Carmona, Eva M. , Carmona, Eva M , Kottom, Theodore J , Limper, Andrew H.

Mayo Clinic

The Journal of Infectious Diseases | July 20, 2021 | Volume: 225 | Issue: 3 | Pages: 525-530

10.1093/infdis/jiab384 | PMID 34289046 Get It

Abstract Pneumocystis species interaction with myeloid cells is well known, especially in macrophages; however, how the organism binds to lung epithelial cells is incompletely understood. Ephrin type-A receptor 2 (EphA2) has been previously identified as a lung epithelial pattern recognition receptor that binds to fungal β-glucans. Herein, we also report that EphA2 can also bind Pneumocystis β-glucans, both in isolated forms and also on exposed surfaces of the organism. Furthermore, binding of Pneumocystis β-glucans resulted in phosphorylation of the EphA2 receptor, which has been shown to be important for downstream proinflammatory response. Indeed, we also show that interleukin 6 cytokine is significantly increased when lung epithelial cells are exposed to Pneumocystis β-glucans, and that this response could be blocked by preincubation with a specific antibody to EphA2. Our study presents another Pneumocystis lung epithelial cell receptor with implications for initial colonization and possible therapeutic intervention.
Acute Exercise Enhances The Ex Vivo Expansion And Cytolytic Phenotype Of Cytokine Induced Killer Cells
Gustafson, Michael P. , Zúñiga, Tiffany M. , Baker, Forrest L. , Smith, Kyle A. , Katsanis, Emmanuel , Simpson, Richard J.

Mayo Clinic

Medicine & Science in Sports & Exercise | July 12, 2021 | Volume: 53 | Issue: 8S | Pages: 366-366

10.1249/01.mss.0000763512.92841.7f Get It

Prognostic impact of posttransplant FDG PET/CT scan in multiple myeloma
Kaddoura, Marcella , Dingli, David , Buadi, Francis K. , Lacy, Martha Q. , Kapoor, Prashant , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Lust, John A., Lin, Yi , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Dispenzieri, Angela , Fonder, Amie , Leung, Nelson , Kourelis, Taxiarchis , Broski, Stephen M , Rajkumar, S Vincent , Kumar, Shaji K , Tschautscher, Marcella , Buadi, Francis K , Dingli, David , Lin, Yi , Gertz, Morie A. , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I. , Broski, Stephen M. , Rajkumar, S. Vincent

Mayo Clinic

Blood Advances | July 10, 2021 | Volume: 5 | Issue: 13 | Pages: 2753-2759

10.1182/bloodadvances.2020004131 | PMID 34242392 Get It

Abstract Multiple myeloma (MM) is a heterogeneous disease that may be evaluated by a broad array of imaging and laboratory techniques to measure disease activity and predict prognosis. Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) scanning has been shown to be predictive of patient outcomes throughout the disease course. We sought to corroborate these findings by examining the prognostic impact of PET/CT scanning in the posttransplant setting. We retrospectively analyzed PET/CT scans in 229 MM patients receiving an autologous stem cell transplant (ASCT) near day 100, and correlated these findings with time to progression(TTP) and overall survival (OS) to assess the impact of day 100 PET/CT scan findings as an independent prognostic factor. The median OS for the entire cohort was 61.5 months (95% confidence interval [CI], 49-75) and the median TTP was 18.5 months (95% CI, 15.4-21.8). Among patients with abnormal day 100 PET findings (PET+), median TTP was 12.4 months vs 24 months among those with normal PET findings (PET−) (P < .0001). The median OS in the PET+ group was 46 months compared with 99 months in the PET− group (P < .0001). We conclude that an abnormal PET/CT scan near day 100 post-ASCT is predictive of shorter TTP and OS, with prognostic significance retained after adjusting for disease response and other prognostic variables in MM.
A proposed framework for cerebral venous congestion
Arun, Anirudh , Higgins, Nicholas , Brinjikji, Waleed , Sattur, Mithun G. , Luciano, Mark G. , Meng, Ran , Satti, Sudhakar R , Amans, Matthew R. , Nakaji, Peter , Huisman, Thierry A.G.M. , Moghekar, Abhay , Mendes Pereira, Vitor , Fargen, Kyle M , Hui, Ferdinand

Mayo Clinic

The Neuroradiology Journal | July 5, 2021 | Volume: 35 | Issue: 1 | Pages: 94-111

10.1177/19714009211029261 | PMID 34224274 Get It

Background While venous congestion in the peripheral vasculature has been described and accepted, intracranial venous congestion remains poorly understood. The characteristics, pathophysiology, and management of cerebral venous stasis, venous hypertension and venous congestion remain controversial, and a unifying conceptual schema is absent. The cerebral venous and lymphatic systems are part of a complex and dynamic interaction between the intracranial compartments, with interplay between the parenchyma, veins, arteries, cerebrospinal fluid, and recently characterized lymphatic-like systems in the brain. Each component contributes towards intracranial pressure, occupying space within the fixed calvarial volume. This article proposes a framework to consider conditions resulting in brain and neck venous congestion, and seeks to expedite further study of cerebral venous diagnoses, mechanisms, symptomatology, and treatments. Methods A multi-institution retrospective review was performed to identify unique patient cases, complemented with a published case series to assess a spectrum of disease states with components of venous congestion affecting the brain. These diseases were organized according to anatomical location and purported mechanisms. Outcomes of treatments were also analyzed. Illustrative cases were identified in the venous treatment databases of the authors. Conclusion This framework is the first clinically structured description of venous pathologies resulting in intracranial venous and cerebrospinal fluid hypertension. Our proposed system highlights unique clinical symptoms and features critical for appropriate diagnostic work-up and potential treatment. This novel schema allows clinicians effectively to approach cases of intracranial hypertension secondary to venous etiologies, and furthermore provides a framework by which researchers can better understand this developing area of cerebrovascular disease.
Abstract 19169: Anakinra - A Promising New Therapy for Idiopathic Recurrent Pericarditis
Espinosa, Raúl E. , Klarich, Kyle W. , Anavekar, Nandan S., Moder, Kevin G., Oh, Jae K. , Matteson, Eric L. , Jain, Sonia , Thongprayoon, Charat , Hayes, Sharonne N.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 130 | Issue: suppl_2 | Pages: No page available

10.1161/circ.130.suppl_2.19169 Get It

BACKGROUND: Idiopathic recurrent pericarditis (IRP) is a debilitating condition that can be recalcitrant to conventional therapy. Some patients develop steroid dependency with the attendant risks of systemic side effects and increased future recurrence. Anakinra is a recombinant human interleukin-1 receptor antagonist that reduces systemic inflammatory responses. The aim of this study was to evaluate the therapeutic role of anakinra in IRP. Methods: We retrospectively studied consenting patients with treatment refractory IRP who received anakinra, between January 2009 and November 2013. The primary end points were symptom resolution and steroid discontinuation. Results: Nine patients were followed for a median of 16.8 (IQR 1.3-24) months. Study subjects were predominantly female (7 [78%]) with a median age of 53 (IQR 38 - 58) years. All 9 patients had failed maximum tolerated doses of NSAIDs, colchicine and prednisone (median dose 20 mg [IQR 15 - 22.5]). Primary symptom was chest pain in 9 (100%), with concurrent dyspnea in 5 (56%) patients. Symptom duration prior to anakinra initiation was 24 (IQR 13 - 71) months. Indication for anakinra was steroid sparing agent in 7 (78%) and symptom control in 2 (22%) patients. The dosage was 100 mg once daily via subcutaneous injection. Baseline LVEF was 62% (IQR 59% - 67%). Echocardiographic findings include pericardial effusion in 3 (33%), pericardial thickening in 6 (67%), and constrictive physiology in 4 (44%). Pericardial enhancement on cardiac MRI was seen in 7 (78%) patients. All 9 patients (100%) had symptom improvement with complete resolution in 8 (89%) and partial resolution in 1 (11%) patient. At last follow up, all 9 (100%) patients had discontinued NSAIDs and colchicine, 5 (56%) patients discontinued and 4 (44%) had reduced prednisone dosage. All patients remained on anakinra at the end of follow up. The only reported side effect was transient injection site reaction in 4 (44%) patients. In 2 (22%) patients, attempted anakinra weaning was unsuccessful due to symptomatic flare after 6 weeks. Conclusion: Anakinra is an effective alternative agent for the management of steroid dependent IRP. It provides remarkable symptomatic amelioration, limits steroid dependency, and is associated with minimal side effects.
Abstract 3265: A Comparison of Echocardiographic and Electrocardiographic Characteristics of Patients with Apical Hypertrophic Cardiomyopathy
Binder, Josepha, Jost, Christine Attenhofer, Klarich, Kyle W. , Ackerman, Michael J. , Tajik, A. Jamil , Ommen, Steve R. , Grossardt, Brandon R.

Mayo Clinic

Circulation | July 3, 2021 | Volume: 116 | Issue: suppl_16 | Pages: No page available

10.1161/circ.116.suppl_16.ii_734-c Get It

Background: Apical hypertrophic cardiomyopathy (apical HCM) is a less common subtype of HCM characterized by a focal thickening in the left ventricular apex. “Classic” ECG features have been described, however, apical HCM can persist for many years without detection. We investigated the relationship between ECG findings and echocardiographic morphometry in a large referral series of patients with apical HCM. Methods: We enumerated all patients diagnosed with apical HCM prior to Sept. 30, 2006 using the Mayo Clinic HCM database. We compared echocardiographic measures separately for patients with positive status for two ECG indices of left ventricular hypertrophy (LVH); the Sokolow-Lyon index and the Romhilt-Estes (RE) point-score. We also compared echocardiographic measurements in patients with and without negative T-waves in the precordial leads. Results: Apical HCM was detected in 177 patients (111 men and 68 women). Only 51% had positive Sokolow criteria and 51% had positive RE criteria. The agreement between Sokolow and RE status was high (agreement = 75.0%; kappa = 0.50; 95% CI = 0.38 – 0.62). In particular, Sokolow positive patients had increased LV ejection fraction (P = 0.02), and decreased LV end-systolic diameter (P = 0.03) compared with Sokolow negative patients. The prevalence of right atrial enlargement (47 vs. 28%; P = 0.02) and intracavity obstruction (22 vs. 8%; P = 0.01) were more common in Sokolow positive patients. Positive RE criteria was associated with a greater thickness of the basal septal and basal posterior walls (P = 0.001 and 0.02, respectively), and with a higher frequency of intracavity obstruction (21 vs. 9%; P = 0.04). Most patients (89%) exhibited at least one negative T-wave in the precordial leads; however, only 10% of patients had a negative T-wave of greater than 1.0 mV. We found that patients with an inverted T-wave larger than 0.4 mV (median) had a significantly increased LV ejection fraction (P = 0.03) compared with patients who had smaller or no negative T-waves. Conclusions: Among patients with apical HCM, nearly half do not have ECG evidence of LVH based on classic criteria and most do not have marked T-wave inversions. However, the majority did have at least a mild expression of negative T-waves.